This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Yttrium-90 Clivatuzumab Tetraxetan
Drug Names(s): 90Y-Clivatuzumab Tetraxetan, humanized anti-MUC1 monoclonal antibody with Yttrium-90, Y-90 hPAM4
Description: hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas, or most other normal tissues. Preclinical studies with PAM4 labeled with the radioisotope Yttrium-90 demonstrated faborable tumor responses, which could be further improved when given in combination with gemcitabine.
Yttrium-90 Clivatuzumab Tetraxetan News
Pink Sheet Pancreatic Cancer Drugs In Development
Additional information available to subscribers only: